The goal of this clinical trial is to learn if the use of MRI-guided irradiation increases the rates of bladder preservation as well as to decrease complications in patients with muscle invasive bladder cancer who wish to retain their bladders
Karnofsky performance status > 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;
WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr/L; BUN equal or less than 20; serum creatinine equal or less than 2.0.
Prior radiation therapy to the target areas;
Inability to undergo a MRI exam
Single group
MR-guided Radiation Therapy
RadiationMR-guided Radiation Therapy
Pathological complete response rate and Urinary and Rectal Toxicity
A. To achieve pathological complete response rate in 95% of the patients. B. To decrease urinary grade 3 or greater toxicity below 3% and rectal grade 3 or greater toxicity below 1%.
Blood and urine biomarkers, Radiomics biomarkers and PROMs
A. Determination of blood and urine biomarkers of treatment response and toxicity . B. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of urinary functionality with IPSS and Bladder Control Self-Assessment Questionnaire
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
